Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy

Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy

Abstract Objective To provide a greater understanding of the tolerability, safety and clinical outcomes of onasemnogene abeparvovec in real‐world practice, in a broad population of infants with spinal muscular atrophy (SMA). Methods A prospective cohort study of children with SMA treated with onasem...

Full description

Bibliographic Details
Main Authors:	Arlene M. D'Silva, Sandra Holland, Didu Kariyawasam, Karen Herbert, Peter Barclay, Anita Cairns, Suzanna C. MacLennan, Monique M. Ryan, Hugo Sampaio, Nicholas Smith, Ian R. Woodcock, Eppie M. Yiu, Ian E. Alexander, Michelle A. Farrar
Format:	Article
Language:	English
Published:	Wiley 2022-03-01
Series:	Annals of Clinical and Translational Neurology
Online Access:	https://doi.org/10.1002/acn3.51519

Similar Items

Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I
by: Andrada Mirea, et al.
Published: (2021-11-01)

Expanding the Availability of Onasemnogene Abeparvovec to Older Patients: The Evolving Treatment Landscape for Spinal Muscular Atrophy
by: Charlotte A. René, et al.
Published: (2023-06-01)

Treatment of spinal muscular atrophy with Onasemnogene Abeparvovec in Switzerland: a prospective observational case series study
by: Georg M. Stettner, et al.
Published: (2023-02-01)

Is gene therapy in spinal muscular atrophy safe? A casereport of thrombotic microangiopathy following onasemnogene abeparvovec
by: Aleksandra Ziółkiewicz, et al.
Published: (2022-10-01)

Short-Term Safety and Efficacy of Onasemnogene Abeparvovec in 10 Patients with Spinal Muscular Atrophy: Cohort Study
by: Kristina S. Nevmerzhitskaya, et al.
Published: (2021-12-01)

Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy
by: Didu S. T. Kariyawasam, et al.
Published: (2019-08-01)

Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapiesResearch in context
by: Marika Pane, et al.
Published: (2023-05-01)

Changes in electrophysiological findings of spinal muscular atrophy type I after the administration of nusinersen and onasemnogene abeparvovec: two case reports
by: Tomoko Mizuno, et al.
Published: (2023-10-01)

Early Development of Spinal Deformities in Children Severely Affected with Spinal Muscular Atrophy after Gene Therapy with Onasemnogene Abeparvovec—Preliminary Results
by: Venla Soini, et al.
Published: (2023-06-01)

Interim Analysis of Treatment Outcomes of Young Children with 5q Spinal Muscular Atrophy on Gene Replacement Therapy with Onasemnogene Abeparvovec. Clinical Observations
by: Anna A. Kokorina, et al.
Published: (2023-01-01)

Paradoxical increase of neurofilaments in SMA patients treated with onasemnogene abeparvovec-xioi
by: Marina Flotats-Bastardas, et al.
Published: (2023-12-01)

An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER)
by: Rebecca Dean, et al.
Published: (2021-01-01)

Identification of Novel CSF-Derived miRNAs in Treated Paediatric Onset Spinal Muscular Atrophy: An Exploratory Study
by: Arlene M. D’Silva, et al.
Published: (2023-01-01)

Experience of using gene replacement therapy with Zolgensma® (onasemnogene abeparvovec) in real clinical practice in Russia
by: S. B. Artemyeva, et al.
Published: (2022-02-01)

Gene therapy-based strategies for spinal muscular atrophy—an Asia-Pacific perspective
by: Michelle A. Farrar, et al.
Published: (2023-11-01)

Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients
by: Daniel C. Malone, et al.
Published: (2019-01-01)

“We needed this”: perspectives of parents and healthcare professionals involved in a pilot newborn screening program for spinal muscular atrophy
by: Didu S.T. Kariyawasam, MBBS, et al.
Published: (2021-03-01)

"The times they are a-changin'." In reply to El-Zaidy et al.: AVXS-101 (Onasemnogene Abeparvovec) for SMA1: comparative study with a prospective natural history cohort
by: Servais, L
Published: (2019)

Real-World Safety Data of the Orphan Drug Onasemnogene Abeparvovec (Zolgensma<sup>®</sup>) for the SMA Rare Disease: A Pharmacovigilance Study Based on the EMA Adverse Event Reporting System
by: Rosanna Ruggiero, et al.
Published: (2024-03-01)

Newborn screening for Duchenne muscular dystrophy: the perspectives of stakeholdersResearch in context
by: Charli Ji, et al.
Published: (2024-04-01)

Spinal muscular atrophy.
by: Talbot, K, et al.
Published: (2001)

Spinal muscular atrophy
by: D'Amico Adele, et al.
Published: (2011-11-01)

Spinal muscular atrophy (Werdnig‑Hoffmann atrophy disease)
by: Mariana A. RYZNYCHUK, et al.
Published: (2018-06-01)

Rehabilitation in spinal muscular atrophy
by: Agus Iwan Foead, et al.
Published: (2019-01-01)

Rehabilitation in spinal muscular atrophy
by: Joanna Iłżecka
Published: (2021-05-01)

Nusinersen for spinal muscular atrophy
by: Claudia D. Wurster, et al.
Published: (2018-03-01)

Spinal muscular atrophy and ependymoma
by: Aishah Albakr, et al.
Published: (2017-01-01)

Neuronal involvement in muscular atrophy
by: Bruno Alejandro Cisterna, et al.
Published: (2014-12-01)

Recent developments in the treatment of Duchenne muscular dystrophy and spinal muscular atrophy
by: Wendy K. M. Liew, et al.
Published: (2013-05-01)

Modeling spinal muscular atrophy in Drosophila.
by: Chang, H, et al.
Published: (2008)

Spinal muscular atrophy: a perspective outlook
by: M. R. Shaimurzin, et al.
Published: (2020-12-01)

Clinical and biochemical polymorphism of spinal muscular atrophy
by: M. G. Sokolova, et al.
Published: (2017-03-01)

Splice-switching therapy for spinal muscular atrophy.
by: Meijboom, K, et al.
Published: (2017)

The Carrier Frequency of Two <i>SMN1</i> Genes in Parents of Symptomatic Children with SMA and the Significance of <i>SMN1</i> Exon 8 in Carriers
by: Joanne E Davidson, et al.
Published: (2023-07-01)

Chapter 16 Spinal Muscular Atrophy
by: Talbot, K, et al.
Published: (2003)

Metabolic Dysfunction in Spinal Muscular Atrophy
by: Marc-Olivier Deguise, et al.
Published: (2021-05-01)

Mitochondrial Dysfunction in Spinal Muscular Atrophy
by: Eleonora Zilio, et al.
Published: (2022-09-01)

Editorial: Advances in spinal muscular atrophy
by: Jianli Sun
Published: (2023-03-01)

Spinal Muscular Atrophy With Myoclonic Epilepsy
by: Buket ÖZKARA, et al.
Published: (2017-04-01)

Advances in spinal muscular atrophy therapeutics
by: Valeria Parente, et al.
Published: (2018-02-01)